Table 2.

Prevalence of clinical characteristics and autoantibodies in SLE patients stratified by high vs. low IFN-α activity in each ancestral background.

	African-Americans High IFN (%)	African-Americans Low IFN (%)	p-value	European-Americans High IFN (%)	European-Americans Low IFN (%)	p-value	Hispanic-Americans High IFN (%)	Hispanic-Americans Low IFN (%)	p-value
Female	92.3	91.7	0.85	84.6	90.1	0.08	85.4	88.5	0.66
Age (mean years)	39.9	44.2	5.3 × 10−4	40.9	47.2	4.5 × 10−6	34.9	41.2	2.6 × 10−3
Photosensitivity	30.9	37.2	0.19	60.1	56.0	0.40	37.8	56.7	0.010
Discoid Rash	24.6	27.2	0.56	11.9	9.65	0.45	14.6	12.5	0.67
Malar Rash	45.4	40.0	0.28	64.3	57.6	0.17	51.2	50.0	0.87
Oral Ulcers	28.0	25.0	0.50	35.0	39.7	0.32	32.9	35.6	0.71
Serositis	36.2	35.6	0.89	37.8	44.2	0.18	47.6	34.6	0.074
Hematologic	73.9	70.0	0.39	68.5	53.9	2.6 × 10−3	57.3	56.7	0.94
Immunologic	88.4	76.7	2.2×10−3	85.3	75.9	0.019	82.9	77.9	0.46
Neurologic	14.5	16.1	0.66	9.09	14.2	0.12	11.0	7.69	0.44
Renal Disease	42.0	42.8	0.88	29.4	29.0	0.92	45.1	41.3	0.61
Arthritis	78.7	78.3	0.92	79.7	84.7	0.17	52.4	67.3	0.039
ANA	99.0	99.4	0.65	99.3	98.9	0.70	100	95.2	0.044
Anti-dsDNA	40.1	18.9	5.9 × 10−6	45.5	20.4	1.0 × 10−8	42.7	17.3	1.4 × 10−4
Anti-Sm	26.1	8.89	1.2 × 10−5	8.9	1.9	8.8 × 10−4	13.4	5.77	0.072
Anti-RNP	58.9	30.6	2.0 × 10−8	7.69	10.2	0.39	29.2	14.4	0.014
Anti-Ro	44.9	18.9	5.0 × 10−8	33.6	17.2	5.2 × 10−5	41.5	12.5	6.4 × 10−6
Anti-La	13.0	3.89	1.5 × 10−3	11.9	4.29	3.9 × 10−3	15.9	4.81	0.011

% indicates the percentage of subjects in which the specified disease feature is present, Age (mean years) = average of the subjects ages at recruitment, ANA = antinuclear antibody test, p-value is derived from the Chi-square test statistic with one degree of freedom. Bolded entries have a p-value that would remain <0.05 following a Bonferroni correction for the number of variables tested in this analysis.